Sanofi Shares Rise 1.36% Midday After Phase 3 Clinical Success Announcement
Sanofi's stock shows an increase of 1.36% to 80.28 euros this Monday, February 2, 2026, at mid-session, driven by the announcement of a major clinical success. The French pharmaceutical group benefits from positive results for its drug candidate venglustat, while analysts maintain a cautious stance on the matter.
Successful Clinical Trial for Venglustat
Sanofi announced this Monday that its experimental treatment venglustat has met all the primary endpoints in the phase 3 LEAP2MONO clinical trial. This study focused on type 3 Gaucher's disease, a rare genetic metabolic disorder. The French laboratory now plans to initiate international regulatory procedures to obtain the necessary market authorizations. This therapeutic breakthrough comes in a challenging stock market context for the tricolor laboratory, which has seen a decline of 23.66% over twelve months and 9.02% over the last quarter. However, the molecule could provide a new revenue stream in the rare diseases segment, a strategic area for the group as it diversifies its therapeutic portfolio. The upcoming financial meetings, particularly the first-quarter results scheduled for April 23, will provide insight into the overall evolution of the pharmaceutical company.
Financial Community Adjusts Estimates
The financial community has recently adjusted its estimates on the stock. UBS lowered its price target from 105 to 88 euros on January 16, while maintaining a neutral opinion. Citigroup also confirmed a neutral recommendation on January 27, setting a target at 85 euros. These new targets remain above the current price, suggesting an appreciation potential between 6.7% and 10.4%, but they reflect increased caution from analysts regarding the group's prospects. Technically, the stock is trading below its 50 and 200-session moving averages, located at 82.51 and 84.98 euros respectively, indicating a deteriorating underlying trend. The RSI indicator is positioned at 40, in a neutral zone but close to overselling, while the Stochastic signal indicates a buying opportunity. The support level at 77.08 euros is a floor to watch, with immediate resistance at 84.44 euros. The monthly volatility of 7.46% indicates significant fluctuations in an uncertain market environment for the pharmaceutical sector.
